Kenvue (KVUE) Stock Overview
Operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
KVUE Community Fair Values
Create NarrativeSee what 90 others think this stock is worth. Follow their fair value or set your own to get alerts.
Kenvue Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.49 |
| 52 Week High | US$25.17 |
| 52 Week Low | US$14.02 |
| Beta | 0.47 |
| 1 Month Change | -5.66% |
| 3 Month Change | 0.92% |
| 1 Year Change | -23.32% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -34.98% |
Recent News & Updates
Recent updates
Kenvue: Worth Owning As Kimberly-Clark Deal Plays Out
Dec 05Kenvue (NYSE:KVUE) Is Due To Pay A Dividend Of $0.2075
Nov 01
Kenvue (NYSE:KVUE) Is Increasing Its Dividend To $0.2075
Aug 07
Is Kenvue Inc. (NYSE:KVUE) Trading At A 37% Discount?
Jun 23Kenvue's (NYSE:KVUE) Dividend Will Be $0.205
May 13Kenvue (NYSE:KVUE) Is Paying Out A Dividend Of $0.205
Apr 24Kenvue Inc.'s (NYSE:KVUE) Share Price Matching Investor Opinion
Apr 22Kenvue: How To Profit Strongly, Despite Elusive Upside
Mar 25These 4 Measures Indicate That Kenvue (NYSE:KVUE) Is Using Debt Reasonably Well
Mar 25Looming Challenges, But Kenvue Could Become A Compelling Dividend Growth Stock Beyond 2025
Feb 17Kenvue Is A Mediocre Candidate
Feb 08Kenvue: Lots Of Potential, But Short-Term Upside May Be Tapped Out (Rating Downgrade)
Nov 27Kenvue: Unpacking Activist's Case And Earnings Preview
Oct 29Kenvue: Turning Cautious On The Stock While Remaining Optimistic On The Business
Oct 02
Critical Brand Investments And Operational Efficiencies Set To Spur Robust Growth And Investor Confidence
Strategic investments in brand marketing and launching new products like Tylenol Easy To Swallow aim at enhancing market penetration and consumer loyalty.Kenvue: Promising Steps Toward Long-Term Success
Aug 11Kenvue Is A Premier Consumer Company, But I Am Waiting For A Lower Price Before I Buy
Aug 02Shareholder Returns
| KVUE | US Personal Products | US Market | |
|---|---|---|---|
| 7D | -4.9% | -5.3% | -1.6% |
| 1Y | -23.3% | -11.7% | 17.7% |
Return vs Industry: KVUE underperformed the US Personal Products industry which returned -12% over the past year.
Return vs Market: KVUE underperformed the US Market which returned 20.4% over the past year.
Price Volatility
| KVUE volatility | |
|---|---|
| KVUE Average Weekly Movement | 2.7% |
| Personal Products Industry Average Movement | 8.9% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: KVUE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KVUE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 21,890 | Kirk Perry | www.kenvue.com |
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women’s health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements.
Kenvue Inc. Fundamentals Summary
| KVUE fundamental statistics | |
|---|---|
| Market cap | US$33.33b |
| Earnings (TTM) | US$1.47b |
| Revenue (TTM) | US$15.12b |
Is KVUE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KVUE income statement (TTM) | |
|---|---|
| Revenue | US$15.12b |
| Cost of Revenue | US$6.30b |
| Gross Profit | US$8.83b |
| Other Expenses | US$7.36b |
| Earnings | US$1.47b |
Last Reported Earnings
Dec 28, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.77 |
| Gross Margin | 58.37% |
| Net Profit Margin | 9.72% |
| Debt/Equity Ratio | 77.9% |
How did KVUE perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/13 13:05 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/12/28 |
| Annual Earnings | 2025/12/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kenvue Inc. is covered by 21 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lauren Lieberman | Barclays |
| Lauren Lieberman | Barclays |
| Navann Ty Dietschi | BNP Paribas |